The Management Board of Xenios AG, the Heart & Lung Business Unit of Fresenius Medical Care, has been restructured. Effective January 31, 2021, the previous Chair of the Executive Board, Dr. Andreas Terpin, has left the company. The new senior trio on the Management Board will continue Fresenius Medical Care’s success in the field of extracorporeal heart & lung therapies.
The Management Board contract with Dr. Andreas Terpin ended on January 31, 2021. After three successful years at Xenios AG, Dr. Terpin is pursuing new projects at Fresenius Medical Care.
As part of this, Mr. Jörg Buschbell and Mr. Stefan Kretzschmar were appointed as members of the Management Board of Xenios AG. Both come from Fresenius Medical Care, the world’s leading provider of products and services for people with kidney diseases, and have already held management positions at Xenios AG for several years. Dr. Jürgen Böhm remains on the Management Board as the third member.
Responsibilities are divided up as follows on the Management Board: Mr. Jörg Buschbell is responsible for sales and operating activities, while Mr. Stefan Kretzschmar focuses on finance. Dr. Jürgen Böhm remains responsible, among other things, for medical management and all quality issues. This newly established leadership will ensure the next important steps towards the success of Fresenius Medical Care and Xenios AG in the field of extracorporeal heart & lung therapies.
On behalf of the company, the Supervisory Board of Xenios AG would like to thank Dr. Terpin most sincerely for his significant contribution to the successful development of Xenios AG in recent years. He leaves behind a well-established and stable company, especially after a very challenging yet successful year in 2020.